FI111442B - Menetelmä stabiilin, vesipitoisen farmaseuttisen koostumuksen valmistamiseksi - Google Patents

Menetelmä stabiilin, vesipitoisen farmaseuttisen koostumuksen valmistamiseksi Download PDF

Info

Publication number
FI111442B
FI111442B FI955136A FI955136A FI111442B FI 111442 B FI111442 B FI 111442B FI 955136 A FI955136 A FI 955136A FI 955136 A FI955136 A FI 955136A FI 111442 B FI111442 B FI 111442B
Authority
FI
Finland
Prior art keywords
ifn
gamma
interferon
preservative
interferon gamma
Prior art date
Application number
FI955136A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI955136A (fi
FI955136A0 (fi
Inventor
Tue Nguyen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FI955136A publication Critical patent/FI955136A/fi
Publication of FI955136A0 publication Critical patent/FI955136A0/fi
Application granted granted Critical
Publication of FI111442B publication Critical patent/FI111442B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FI955136A 1993-05-12 1995-10-27 Menetelmä stabiilin, vesipitoisen farmaseuttisen koostumuksen valmistamiseksi FI111442B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6032793A 1993-05-12 1993-05-12
US6032793 1993-05-12
PCT/US1994/004928 WO1994026302A1 (en) 1993-05-12 1994-05-04 Stable liquid compositions of gamma interferon
US9404928 1994-05-04

Publications (3)

Publication Number Publication Date
FI955136A FI955136A (fi) 1995-10-27
FI955136A0 FI955136A0 (fi) 1995-10-27
FI111442B true FI111442B (fi) 2003-07-31

Family

ID=22028807

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955136A FI111442B (fi) 1993-05-12 1995-10-27 Menetelmä stabiilin, vesipitoisen farmaseuttisen koostumuksen valmistamiseksi

Country Status (23)

Country Link
EP (1) EP0697887B1 (pl)
JP (1) JP4053586B2 (pl)
KR (1) KR100330325B1 (pl)
CN (1) CN1120724C (pl)
AT (1) ATE173632T1 (pl)
AU (1) AU683469B2 (pl)
CA (1) CA2159602C (pl)
CZ (1) CZ285389B6 (pl)
DE (1) DE69414841T2 (pl)
DK (1) DK0697887T3 (pl)
ES (1) ES2126114T3 (pl)
FI (1) FI111442B (pl)
GR (1) GR3029286T3 (pl)
HK (1) HK1008303A1 (pl)
HU (1) HUT72980A (pl)
IL (1) IL109350A (pl)
NO (1) NO320069B1 (pl)
NZ (1) NZ266354A (pl)
PL (1) PL176079B1 (pl)
SK (1) SK280958B6 (pl)
TW (1) TW275585B (pl)
WO (1) WO1994026302A1 (pl)
ZA (1) ZA942955B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
DK0862452T3 (da) * 1995-11-07 2004-04-05 Genentech Inc Stabiliserende formulering af NGF
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
US6964947B1 (en) 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
JP3493866B2 (ja) * 1995-12-27 2004-02-03 ライオン株式会社 発泡性口腔用組成物
PE63998A1 (es) * 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
US6281212B1 (en) 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
ES2224290T5 (es) * 1996-12-24 2012-03-12 Biogen Idec Ma Inc. Formulaciones l�?quidas estables de interferón.
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
AU4445201A (en) * 2000-03-30 2001-10-08 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
EP1516627A1 (en) * 2003-09-17 2005-03-23 CONARIS research institute AG Interferon-Gamma for the treatment of diseases associated with the NOD2 gene
JP5137055B2 (ja) * 2006-03-10 2013-02-06 塩野義製薬株式会社 安定化されたインターフェロン−γ組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) * 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
EP0308181A1 (en) * 1987-09-14 1989-03-22 Novo Nordisk A/S Trans-mucosal delivery formulations and a method for preparation thereof
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation

Also Published As

Publication number Publication date
ATE173632T1 (de) 1998-12-15
FI955136A (fi) 1995-10-27
SK137895A3 (en) 1997-02-05
CA2159602A1 (en) 1994-11-24
TW275585B (pl) 1996-05-11
HU9503223D0 (en) 1996-01-29
NO954544D0 (no) 1995-11-10
EP0697887B1 (en) 1998-11-25
NO320069B1 (no) 2005-10-17
JPH08510242A (ja) 1996-10-29
PL311639A1 (en) 1996-03-04
GR3029286T3 (en) 1999-05-28
CZ285389B6 (cs) 1999-07-14
AU6782294A (en) 1994-12-12
NZ266354A (en) 1997-06-24
JP4053586B2 (ja) 2008-02-27
KR100330325B1 (ko) 2002-11-01
HUT72980A (en) 1996-06-28
CA2159602C (en) 2008-08-26
PL176079B1 (pl) 1999-04-30
AU683469B2 (en) 1997-11-13
DK0697887T3 (da) 1999-08-09
ES2126114T3 (es) 1999-03-16
ZA942955B (en) 1995-10-30
KR960702320A (ko) 1996-04-27
IL109350A0 (en) 1994-07-31
CZ295595A3 (en) 1996-04-17
IL109350A (en) 2001-01-28
CN1122575A (zh) 1996-05-15
DE69414841D1 (de) 1999-01-07
DE69414841T2 (de) 1999-06-02
HK1008303A1 (en) 1999-05-07
NO954544L (no) 1995-11-10
FI955136A0 (fi) 1995-10-27
WO1994026302A1 (en) 1994-11-24
CN1120724C (zh) 2003-09-10
EP0697887A1 (en) 1996-02-28
SK280958B6 (sk) 2000-10-09

Similar Documents

Publication Publication Date Title
FI111442B (fi) Menetelmä stabiilin, vesipitoisen farmaseuttisen koostumuksen valmistamiseksi
ES2286868T3 (es) Composicion acuosa a base de hormana del crecimiento humana.
CA2275890C (en) Stable liquid interferon formulations
AU2005249233B2 (en) Stabilized interferon liquid formulations
US9522174B2 (en) Stable liquid interferon beta formulations
US20050244373A1 (en) Composition for treatment of and method of monitoring hepatitis C virus using interferon-tau
JPH10506912A (ja) 安定な、水性αインターフェロン溶液処方物
EP2585044B1 (en) Long-term storage of non-glycosylated recombinant human g-csf
RU2823074C2 (ru) Варианты свиного g-csf и их применение
KR102619071B1 (ko) 돼지 g-csf 변이체 및 그 용도
WO2021245541A1 (en) A composition of pegylated interferon alpha-2b for the treatment of sars-cov-2 infection and related manifestations

Legal Events

Date Code Title Description
MA Patent expired